EHA 2019 | Glasdegib therapy for MDS and AML

David Sallman

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the use of glasdegib therapy for relapsed/refractory myelodysplastic syndromes and oligoblastic acute myeloid leukemia at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  
Similar topics